Adtralza (tralokinumab)

Active substance   tralokinumab
Holder LEO Pharma
Status Running
Indication severe atopic dermatitis in adolescent patients (12- <18 years) who are candidates for systemic treatment (including patients coming from the Open Label Extension Study ECZTEND – LP0162-1337 with EudraCT reference 2018-000746-19)
Public documents Approbation
  Information for the patient
  Informed consent
Laste update 05/08/2022

 

Last updated on 28/09/2022